治疗更年期女性血管舒缩症状的新药Fezolinetant
Fezolinetant,a new approved drug for the treatment of vasomotor symptoms in menopausal women
卞婷婷 1何心2
作者信息
- 1. 扬州市妇幼保健院,扬州大学附属扬州妇幼保健院药学部,江苏扬州 225000
- 2. 南京医科大学附属妇产医院、南京市妇幼保健院药学部,江苏南京 210004
- 折叠
摘要
Fezolinetant于2023年5月由美国食品药品监督管理局(FDA)正式批准用于治疗更年期妇女的中至重度血管舒缩症状(VMS).Fezolinetant是一种神经激肽3受体(NK3R)拮抗药,能够拮抗神经激肽B与KNDy神经元结合,从而减少VMS发作次数、改善VMS严重程度.本文对其作用机制、药效学、药代动力学、临床研究及安全性等做一介绍.
Abstract
Fezolinetant has been approved by the U.S.Food and Drug Administration(FDA)for the treatment of moderate/severe vasomotor symptoms(VMS)in menopausal women.The Fezolinetant tablet is for oral use and is a neurokinin 3 receptor(NK3R)antagonist that blocks neurokinin B binding on the KNDy neuron.Clinical studys indicate that Fezolinetant can reduce the frequency and severity of VMS and improve quality of life.The mechanism of action,pharmacodynamics,pharmacokinetics,clinical study and safety were introduced.
关键词
Fezolinetant/血管舒缩症状/更年期妇女/非激素疗法Key words
Fezolinetant/vasomotor symptoms/menopausal women/non-hormone therapy引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据